LONGMONT, Col. –AGC Biologicstoday announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at itscommercial-grade campusin Longmont, Col., USA. These new capabilities, which begin coming online in the third quarter of 2022, complement the campus’ adherent viral vector and cell therapy offerings — enabling AGC Biologics to provide an in-depth variety of end-to-end cell and gene therapy services at this site.
An aerial view of AGC Biologic's campus in Longmont, Col., USA. Image courtesy of AGC Biologics.
North America has historically been home to more advanced therapy and regenerative medicine developers than any other region worldwide. Further, the 2021Q3Cell & Gene Therapies Market Outlookreport from industry standard research (ISR) revealed viral vectors are the most common thing a drug developer needs from a CDMO. This expansion more than doubles the site’s viral vector capacity, and helps AGC Biologics meet these market demands.
“This investment helps AGC Biologics address the needs of gene therapy developers at our new central location in North America,” said Patricio Massera, CEO of AGC Biologics. “When you combine these new capabilities and the technical expertise at our Longmont campus, with our Milan facility’s lentiviral vector platform and its extensive gene therapy CDMO experience, we can now support virtually any viral vector program being developed anywhere in the world.”
The viral vector suspension expansion is a part of a more than $30 million investment by AGC Biologics in its new Longmont campus. The new suspension capabilities include a full complement of bioreactor sizes for product development (AMBR, 10L and 50L), and a complete range of commercial manufacturing capacities (50L, 200L, 500L and 2000L), enabling the site to provide support for the entire lifecycle of a product.
“The suspension expansion helps us offer the most impactful, efficient and scalable technologies for bringing viral vector-based gene therapy products to market,” said Tony Fraij, General Manager, AGC Biologics Longmont. “This latest investment helps us round out the services we offer at this campus. Now, with a full suite of capabilities and the extensive expertise of our scientists, we can support virtually any type of viral vector or cell therapy development and manufacturing project.”
AGC Biologic's campus in Longmont, Col., USA. Image courtesy of AGC Biologics.
AGC Biologicsacquired the Longmont campusin August of 2021 andquickly appointed Fraij, a 20-year veteran with experience leading operations at several global life science organizations. The company previously acquired a cell and gene therapy site in Milan, Italy fromMolMed S.p.A. in 2020. The AGC Biologics Milan team’s technical expertise will play an important informative role in launching the new viral vector capabilities in Longmont. In just a few short years the company built a strong global cell and gene therapy network of services, capabilities and scientists. AGC Biologics is one of only a few CDMOs with end-to-end cell advanced therapies on two continents.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
With over 15 years of leadership in contract process development and manufacturing, AGC Biologics offers a deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics. The company’s 850 dedicated employees are committed to providing solutions for more than 100 customers on five continents. Headquartered in Seattle, AGC’s integrated service offerings include, amongst other things, cell line and bioprocess development, antibody drug development and conjugation and protein expression.